On Wednesday, U.S. Department of Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr., U.S. Food and Drug Administration (FDA) Commissioner
Marty Makary and Centers for Medicare & Medicaid Services (CMS) Administrator
Dr. Mehmet Oz made an announcement on accelerating biosimilar approvals,
boosting competition and lowering prescription drug prices.
October 31, 2025
TOPLINE
On Wednesday, U.S. Department of Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr., U.S. Food and Drug Administration (FDA) Commissioner
Marty Makary and Centers for Medicare & Medicaid Services (CMS) Administrator
Dr. Mehmet Oz made an announcement on accelerating biosimilar approvals,
boosting competition and lowering prescription drug prices. The
administration’s actions will include updated FDA guidance to eliminate
comparative efficacy study requirements and streamline biosimilar approvals — a
move that could significantly reduce barriers to fostering greater competition
from more affordable alternatives to Big Pharma’s high-priced biologic drugs.
“CSRxP applauds the administration for taking steps to increase biosimilar
competition and bring down costs for patients, taxpayers and the U.S. health
care system,” said CSRxP executive director Lauren Aronson in astatement
<[link removed]>
. “Actions to eliminate unnecessary red tape and streamline biosimilar
approvals will help bring more affordable alternatives to market faster,
boosting competition and delivering prescription drug savings for patients.
[This] announcement represents an important step toward strengthening
competition in the prescription drug marketplace, expanding access to safe,
effective, lower-cost treatments, and holding Big Pharma accountable for
blocking more affordable options.”
Read CSRxP’s full statement on the announcement HERE
<[link removed]>
and read more about how biosimilar competition generates significant savings
for American patients and the U.S. health care systemHERE
<[link removed]>
.
On Monday, the Institute for Clinical and Economic Review (ICER) released a new
report
<[link removed]>
which found that Big Pharma’s launch prices for prescription drugs newly
entering the market continue to increase, without accompanying justification
based on clinical value. According to ICER’s 2025 “Launch Price and Access
Report,” the inflation-adjusted median annual list price for newly launched
drugs increased 24 percent between 2022 and 2024. The report underscored these
rising and unsustainably high prices tags are not justified by clinical value
for patients. “The U.S. health system could’ve saved between $1.3 billion and
$1.5 billion in just the first year post-approval” of these new medications if
Big Pharma “stuck with the upper limit for price on what the watchdog suggested
[would be justified by clinical value] prior to the launch of 23 drugs formerly
reviewed by ICER.”
Read more on the new ICER report HERE
<[link removed]>
.
QUOTE OF THE WEEK
“Since 2015, biosimilars have already saved Americans over $56 billion, $20
billion in 2024 alone. On average, biosimilars cost 50 percent less than their
brand-name counterparts, and their entry into the market drives down brand-name
prices by another 25 percent. That's real relief for patients, families, and
for the American taxpayer.”
HHS Secretary Robert F. Kennedy Jr.
<[link removed]>
DATA POINTS YOU SHOULD KNOW
$308,749
The inflation-adjusted median annual list price for newly launched drugs in
2024 – according to a newreport
<[link removed]>
from ICER – a 24 percent increase from 2022.
TWEETS OF THE WEEK
@HHSResponse <[link removed]>:
“.@SecKennedy: ‘We’re cutting unnecessary red tape, reducing uncertainty, and
making it easier for innovators to bring safe, affordable biosimilars to the
market.’”
@DrMakaryFDA <[link removed]>:
“Biologics are 5% of prescriptions — but 51% of drug spending. @US_FDA is going
to accelerate biosimilar alternatives to make these amazing medicines more
affordable for Americans.”
ROAD TO RECOVERY
The New York Times: F.D.A. Moves To Speed Approvals For Cheaper Copycat Drugs
<[link removed]>
The Food and Drug Administration announced on Wednesday that it would ease
regulatory roadblocks for low-cost copycat versions of certain medicines.
Biosimilars, as the copycats are called, are seen as a crucial way to drive
down drug prices. They are akin to generics of biologic drugs that are made
through complex biological processes. Some well-known blockbuster drugs are now
available as biosimilar competitors, including Herceptin, for breast cancer;
Lantus, a widely used insulin; and Humira, for autoimmune conditions like
arthritis.
STAT News: FDA Moves To Ease Path For Biosimilars As Trump Seeks To Cut Drug
Costs
<[link removed]>
The Trump administration announced a draft framework Wednesday that officials
say will speed cheaper versions of biologic drugs to market with the aim of
making medicine more affordable and accessible for patients. The framework will
shorten the path for the Food and Drug Administration to approve biosimilars,
or copycat versions of biologic drugs, by lowering the clinical standards
companies need to meet before bringing the drugs to market. That will cut the
cost of developing biosimilars and the time needed to approve them, FDA
Commissioner Marty Makary said at an announcement about the change. Makary said
the agency plans to release its final guidance on biosimilars in three to six
months.
Financial Times: US Set To Speed Up Generic Biological Drug Approvals
<[link removed]>
The US drugs regulator is preparing to accelerate approvals for cheaper
generic versions of complex biological medicines, threatening to jeopardise
revenue for some of the industry’s most profitable products. The US Food and
Drug Administration is expected to take measures on Wednesday that include
reducing the number of certain human clinical studies and cutting costs of
medicines engineered with living cells. The changes would come despite fierce
lobbying by the industry’s top representatives in Washington, who have spent
millions of dollars to derail less-expensive biological options.
Inside Health Policy: CSRxP Applauds Administration For Commitment To
Fostering Greater Biosimilar Competition, Lowering Drug Prices For American
Patients
<[link removed]>
The Campaign for Sustainable Rx Pricing (CSRxP) today applauded an
announcement by U.S. Department of Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr., U.S. Food and Drug Administration (FDA) Commissioner
Marty Makary and Centers for Medicare & Medicaid Services (CMS) Administrator
Dr. Mehmet Oz to accelerate biosimilar approvals, boosting competition and
lowering prescription drug prices for millions of Americans.
PHARMA’S POOR PROGNOSIS
Inside Health Policy: ICER: U.S. Drug Launch Prices Continue To Rise, ICER
Value-Based Approach Better Than MFN
<[link removed]>
A report from the Institute for Clinical and Economic Review (ICER) released
Thursday (Oct. 23) found drug launch prices are rising at higher rates than
inflation, gross domestic product growth (GDP) and health care costs, and if
prices matched ICER’s value-based estimates, $1.3-1.5 billion could have been
saved in the first-year pricing.
Law360: Whistleblower 'Horrified' By Novo Nordisk Drug Sales Tactics
<[link removed]>
The whistleblower behind a federal lawsuit accusing Novo Nordisk of paying
kickbacks to doctors and patients as part of a scheme to drive sales of its
hemophilia drug NovoSeven took the witness stand Monday, telling jurors she was
"horrified" at how the drugmaker's marketing team targeted doctors. Jamie
Siegel, a doctor on Novo Nordisk's clinical development team from 2008 to 2009,
testified that she was pressured by the company to encourage her connections in
the hemophilia community to promote off-label use of NovoSeven.
###
Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx
This email was sent to
[email protected]. To unsubscribe please click
here.
<[link removed]>
